Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 10, 2020July 10, 2020

FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients

News

Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for hard-to-treat patients with multiple myeloma. ... Read more

June 17, 2020June 17, 2020

Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled

News

A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled, Oncopeptides, the treatment’s developer, announced. The OCEAN trial (NCT03151811) ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 9, 2020March 9, 2020

Xpovio Combo Significantly Extends Survival in RRMM, Trial Results Show

News

Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with multiple myeloma who received one to three prior lines of ... Read more

February 21, 2020February 21, 2020

Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says

News

Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive distribution agreement announced by the treatment’s maker, Karyopharm ... Read more

February 17, 2020February 17, 2020

Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status

News

KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for multiple myeloma, now that the U.S. Food ... Read more

January 24, 2020January 24, 2020

FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced ... Read more

January 21, 2020January 22, 2020

Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients

News

The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). The decision follows a positive opinion issued ... Read more

December 16, 2019December 18, 2019

CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of newly diagnosed multiple myeloma patients who are ... Read more

December 4, 2019December 12, 2019

Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show

News

Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common ... Read more

Pin It on Pinterest